Lipocine Financial Statements From 2010 to 2024

LPCN Stock  USD 4.80  0.25  5.49%   
Lipocine financial statements provide useful quarterly and yearly information to potential Lipocine investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Lipocine financial statements helps investors assess Lipocine's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Lipocine's valuation are summarized below:
Gross Profit
500 K
Market Capitalization
25.7 M
Enterprise Value Revenue
3.7271
Revenue
-2.9 M
Earnings Share
(3.14)
We have found one hundred twenty available fundamental ratios for Lipocine, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Lipocine's last-minute fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 28th of April 2024, Market Cap is likely to drop to about 14 M. In addition to that, Enterprise Value is likely to drop to about 9.5 M

Lipocine Total Revenue

104,488

Check Lipocine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lipocine main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 5.8 M or Total Revenue of 104.5 K, as well as many exotic indicators such as Price To Sales Ratio of 140, Dividend Yield of 0.0048 or PTB Ratio of 0.96. Lipocine financial statements analysis is a perfect complement when working with Lipocine Valuation or Volatility modules.
  
This module can also supplement various Lipocine Technical models . Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.

Lipocine Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets29.7 M23 M25.4 M
Slightly volatile
Other Current Liabilities1.5 M1.2 M1.2 M
Pretty Stable
Total Current Liabilities3.4 M2.6 M2.9 M
Slightly volatile
Other Liabilities196.5 K206.9 K3.3 M
Slightly volatile
Accounts Payable798.8 K1.4 M683.1 K
Slightly volatile
Cash9.2 M4.8 M10.6 M
Pretty Stable
Other AssetsM3.8 MM
Slightly volatile
Cash And Short Term Investments26.6 M22 M22.7 M
Slightly volatile
Common Stock Total Equity10.7 K10.2 KK
Slightly volatile
Common Stock Shares Outstanding5.5 M5.3 M2.2 M
Slightly volatile
Liabilities And Stockholders Equity29.7 M23 M25.4 M
Slightly volatile
Other Current AssetsM773.4 K879.1 K
Slightly volatile
Other Stockholder Equity147.6 M220.1 M126.1 M
Slightly volatile
Total Liabilities5.1 M2.6 M4.4 M
Slightly volatile
Total Current Assets28.8 M22.9 M24.6 M
Slightly volatile
Common Stock9.3 K8.9 K3.9 K
Slightly volatile
Property Plant Equipment124.4 K118.4 K65 K
Pretty Stable
Capital Surpluse143.4 M251 M127.8 M
Slightly volatile
Non Current Assets Total132.9 K139.8 K734 K
Slightly volatile
Property Plant And Equipment Gross1.4 M1.3 M447.2 K
Slightly volatile
Net Receivables49.6 K52.3 K354.2 K
Very volatile
Net Invested Capital27.8 M20.4 M22.5 M
Slightly volatile
Net Working Capital25.5 M20.2 M21.3 M
Slightly volatile
Short and Long Term Debt Total14.7 K15.4 K7.2 M
Slightly volatile
Long Term Debt Total4.3 M3.4 M5.7 M
Slightly volatile
Short and Long Term Debt2.5 M2.1 M3.1 M
Slightly volatile
Capital Stock7.2 K8.9 K4.3 K
Slightly volatile
Short Term Debt14.7 K15.4 K2.6 M
Slightly volatile
Current Deferred Revenue813.2 K914.8 K996.1 K
Slightly volatile
Non Current Liabilities OtherM1.2 M1.3 M
Slightly volatile

Lipocine Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative5.8 M4.9 MM
Slightly volatile
Other Operating Expenses14.5 M15.1 M12.4 M
Slightly volatile
Research Development9.6 M10.1 M1.2 B
Slightly volatile
Cost Of Revenue27.2 K28.7 K7.1 M
Pretty Stable
Total Operating Expenses15.8 M15.1 M6.3 M
Slightly volatile
Non Recurring582.9 K655.8 K714.1 K
Slightly volatile
Tax Provision411613598
Slightly volatile
Reconciled Depreciation24.4 K23.2 K21.5 K
Slightly volatile
Interest Income1.4 M1.4 M284.7 K
Slightly volatile

Lipocine Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow4.5 M4.8 M11.3 M
Pretty Stable
Begin Period Cash FlowM3.1 M11.2 M
Very volatile
Stock Based Compensation1.1 M654.4 K1.3 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio14013466.3399
Pretty Stable
Dividend Yield0.00480.00540.0059
Slightly volatile
Days Sales Outstanding11717374.3493
Slightly volatile
Invested Capital9.0E-40.0010.7562
Slightly volatile
Average Payables641.3 K898.4 K757.5 K
Slightly volatile
Stock Based Compensation To Revenue6.255.95013.3651
Very volatile
EV To Sales94.9790.445162.0232
Pretty Stable
Inventory Turnover1.381.751.5944
Slightly volatile
Days Of Inventory On Hand0.00.0175
Slightly volatile
Payables Turnover0.01950.020512.5888
Pretty Stable
Sales General And Administrative To Revenue46.8244.595216.3558
Slightly volatile
Average Inventory0.40.450.49
Slightly volatile
Research And Ddevelopement To Revenue10392.252689.569
Slightly volatile
Cash Per Share3.974.181618.977
Slightly volatile
Capex To Operating Cash Flow0.00110.00110.0021
Slightly volatile
Days Payables Outstanding18.7 K17.8 K2.5 K
Slightly volatile
Income Quality1.10.72571.3643
Pretty Stable
Current Ratio12.248.687110.7465
Very volatile
Receivables Turnover2.02.104916.3622
Pretty Stable
Graham Number15.6116.42860.8199
Slightly volatile
Debt To Equity9.0E-40.0010.7562
Slightly volatile
Average Receivables590.5 K409.5 K271.4 K
Pretty Stable
Revenue Per Share0.01980.02090.6431
Pretty Stable
Interest Debt Per Share0.00310.00335.4195
Slightly volatile
Debt To Assets8.0E-49.0E-40.3373
Slightly volatile
Operating Cycle15617393.2465
Slightly volatile
Days Of Payables Outstanding18.7 K17.8 K2.5 K
Slightly volatile
Long Term Debt To Capitalization0.140.150.3242
Slightly volatile
Total Debt To Capitalization9.0E-40.0010.3693
Slightly volatile
Debt Equity Ratio9.0E-40.0010.7562
Slightly volatile
Quick Ratio11.678.393210.176
Very volatile
Net Income Per E B T0.81.00.9853
Slightly volatile
Cash Ratio1.721.81325.4324
Slightly volatile
Days Of Inventory Outstanding0.00.0175
Slightly volatile
Days Of Sales Outstanding11717374.3493
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.81.00110.9887
Slightly volatile
Fixed Asset Turnover0.90.9474315
Slightly volatile
Capital Expenditure Coverage Ratio1.5 K9012.3 K
Slightly volatile
Debt Ratio8.0E-49.0E-40.3373
Slightly volatile
Price Sales Ratio14013466.3399
Pretty Stable
Asset Turnover0.00450.00480.0554
Pretty Stable

Lipocine Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap14 M14.7 M75.7 M
Pretty Stable
Enterprise Value9.5 M9.9 M58 M
Very volatile

Lipocine Fundamental Market Drivers

Cash And Short Term Investments22 M

Lipocine Upcoming Events

8th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Lipocine Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Lipocine income statement, its balance sheet, and the statement of cash flows. Lipocine investors use historical funamental indicators, such as Lipocine's revenue or net income, to determine how well the company is positioned to perform in the future. Although Lipocine investors may use each financial statement separately, they are all related. The changes in Lipocine's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lipocine's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Lipocine Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Lipocine. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue914.8 K813.2 K
Total Revenue110 K104.5 K
Cost Of Revenue28.7 K27.2 K
Stock Based Compensation To Revenue 5.95  6.25 
Sales General And Administrative To Revenue 44.60  46.82 
Research And Ddevelopement To Revenue 92.25  103.14 
Capex To Revenue(0.12)(0.13)
Revenue Per Share 0.02  0.02 
Ebit Per Revenue(136.11)(129.30)
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lipocine in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lipocine's short interest history, or implied volatility extrapolated from Lipocine options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Lipocine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipocine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipocine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipocine Stock:
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.
Note that the Lipocine information on this page should be used as a complementary analysis to other Lipocine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for Lipocine Stock analysis

When running Lipocine's price analysis, check to measure Lipocine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipocine is operating at the current time. Most of Lipocine's value examination focuses on studying past and present price action to predict the probability of Lipocine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipocine's price. Additionally, you may evaluate how the addition of Lipocine to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Stocks Directory
Find actively traded stocks across global markets
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
CEOs Directory
Screen CEOs from public companies around the world
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Is Lipocine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.14)
Revenue Per Share
(0.54)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.37)
Return On Equity
(0.58)
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.